Our cytotoxicity and viability assays provide quantitative evaluation of compound-induced cell damage and survival—critical for distinguishing therapeutic efficacy from toxicity in drug discovery. These assays are optimized for high reproducibility and throughput, supporting early-stage compound screening, lead optimization, and preclinical safety assessment for flavivirus inhibitors and other therapeutic candidates.
Colorimetric detection of mitochondrial dehydrogenase activity to measure viable cell number. Optimized for 96/384-well formats with reduced background interference from small molecules.
Readout: Absorbance (570 nm)
Quantification of lactate dehydrogenase (LDH) leakage from damaged cells to assess membrane integrity. Validated for both adherent and suspension cell lines.
Readout: Absorbance (490 nm)
Fluorescence-based dual staining (calcein-AM for live cells, ethidium homodimer for dead cells) for direct visualization and quantification of cell viability via high-content imaging.
Readout: Fluorescence (Ex485/Em535, Ex528/Em617)
Ultra-sensitive detection of intracellular ATP (a marker of metabolically active cells) using luciferase-based luminescence. Ideal for low-cell-number samples and high-throughput screening.
Readout: Luminescence (Relative Light Units)
High-throughput assessment of cytotoxicity for large compound libraries to prioritize candidates with low toxicity profiles.
Comparison of antiviral/therapeutic efficacy (EC50) vs. cytotoxicity (CC50) to determine therapeutic index (TI = CC50/EC50) for lead compounds.
Combination with apoptosis/necrosis markers (e.g., caspase activation, reactive oxygen species) to distinguish cell death mechanisms induced by compounds.
Evaluation of compound toxicity in primary human cells (e.g., hepatocytes, neurons) to predict in vivo safety profiles.